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Abstract 
Promyelocytic Leukaemia Protein nuclear bodies (PML-NBs) are dynamic nuclear protein 
aggregates. To gain insight in PML-NB function, reductionist and high throughput techniques 
have been employed to identify PML-NB proteins. Here we present a manually curated 
network of the PML-NB interactome based on extensive literature review including data-
base information. By compiling ‘the PML-ome’, we highlighted the presence of interactors in 
the Small Ubiquitin Like Modifier (SUMO) conjugation pathway. Additionally, we show an 
enrichment of SUMOylatable proteins in the PML-NBs through an in-house prediction algo-
rithm. Therefore, based on the PML network, we hypothesize that PML-NBs may function as 
a nuclear SUMOylation hotspot.   
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Introduction 
Nuclear domain 10 (also called Kremer bodies 
or PODs) was first observed almost 50 years ago by 
electron microscopy as nuclear dense granular bod-
ies[1, 2]. These punctuate structures are now dubbed 
“PML nuclear bodies” (PML-NBs) after their scaffold 
protein Promyelocytic Leukaemia Protein (PML, also 
known as TRIM19 or MYL). The PML gene consists of 
nine exons and alternative splicing yields six nuclear 
PML isoforms (PML I-VI) and one smaller cytoplas-
matic isoform (PMLVII). However, of these seven 
isoforms there are several alternative spliced variants 
yielding at least 18 different forms of PML[3]. At the 
conserved N-terminus, PML contains a motif that 
defines the TRIM (Tripartite Motif) family of proteins. 
It is characterized by an RBCC motif composed of a 
conserved RING domain, one or two B-boxes, and an 
α-helical coiled-coil domain [4, 5]. The RING domain 
i s  a  c y s t e i n e  r i c h  d o m a i n  w i t h  z i n c  b o u n d  i n  a  
cross-brace conformation. This structure is ideal for 
the formation of larger protein aggregates and there-
fore crucial in processes such as cell growth, onco-
genesis, apoptosis, and RNA trafficking during viral 
infections [5, 6]. The B-box provides the correct ori-
entation and alignment of the coiled-coil domain [7]. 
When correctly positioned, the coiled-coil domain is 
responsible for homo and hetero-dimer interactions 
between TRIM proteins[3]. The RBCC motif of the 
PML protein makes it possible to sustain a highly 
dynamic turnover of partner proteins during the cell 
cycle [8, 9] which could explain the functionally pro-
miscuous nature of the PML-NBs. PML is not only 
responsible for maintaining the integrity of the com-
plex but also for the recruitment and correct localiza-
tion of all PML-NB proteins, e.g. p53, Sp100, Daxx 
and CBP [4]. SUMOylation plays an important role in 
the scaffold function of PML. SUMO-3 attachment Int. J. Biol. Sci. 2010, 6 
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has been reported to be responsible for the correct 
nuclear localization of PML [10], and without SUMO1 
modification several protein partners are not re-
cruited to the PML-NB [10-12]. However, unSU-
MOylatable mutants of PML (3KR) still show the 
typical nuclear speckle pattern [11] indicating that 
also other factors play a role in PML-NB formation. 
Recently, PML was identified as the first protein de-
graded by SUMO-dependent polyubiquitination after 
treatment with arsenic [12]. 
SUMOylation is a post-translational modifica-
tion where one of the four isoforms of the Small 
Ubiquitin-like Modifier (SUMO) protein is conjugated 
to a target protein as a single SUMO molecule 
(SUMO1) or in polymeric chains (SUMO2/3)[13]. The 
enzymatic cascade is similar to the ubiquitin path-
way[14] (Figure 1). However, unlike ubiquitination, 
which targets proteins for degradation, SUMOylation 
modifies proteins to interact in nuclear transport[10, 
15], transcriptional regulation[14, 16], apoptosis[17, 
18] and protein trafficking[19]. 
SUMO is synthesized as a precursor and its 
conjugation requires exposure of two C-terminal gly-
cine residues. The processing of immature SUMO is 
one of the three functions of SUMO specific proteases 
(SENPs). In addition, SENPs are also capable of dis-
mantling SUMO chains and reversing SUMOylation 
by cleaving the isopeptide bonds between SUMO and 
its protein targets or between the several SUMOs[20]. 
Thus far, there are six known SENP isoforms 
(SENP1-3 and SENP5-7)[20] with different assign-
ments in the cascade (Table 1). 
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Figure 1. Schematic representation of the SUMOylation pathway. Before conjugation, immature SUMO is processed by 
SUMO specific proteases (SENPs) to expose two C-terminal glycine residues required for conjugation. After processing, 
mature SUMO is activated in an ATP dependent manner by E1 enzymes AOS1 and UBA2. Subsequently, SUMO is trans-
ferred to E2 conjugation enzyme UBC9 and finally conjugated to a target protein by an E3 ligase. SUMO conjugation can be 
reversed by protease activity of SENPs thereby releasing free SUMO and target. K= Lysine residue. 
 
Table 1. The SENP isoforms show different affinity for the several SUMO isoforms in maturation processing and 
de-conjugation.  
SENP isoform  Maturation  De-conjugation 
SENP1 SUMO1>SUMO2>>SUMO3[21] SUMO1,  SUMO2[22, 23] 
SENP2  SUMO2>SUMO1, poor activity towards SUMO3[24, 25]  SUMO2>SUMO1, poor activity towards SUMO3[24, 25] 
SENP3  No processing activity  SUMO2, SUMO3[26, 27] 
SENP5 SUMO3[26;27] SUMO1[24, 25] 
SENP6  No processing activity[20, 28] SUMO2,  SUMO3[29] 
SENP7  No processing activity[20, 28] SUMO2,  SUMO3>>>SUMO1[28] 
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After maturation, SUMO is activated in an ATP 
dependent manner by thio-ester bond formation with 
the E1 activation proteins UBA2/AOS1[14]. The acti-
vating E1 enzyme Uba2p was first identified in yeast 
where it is, together with Aos1, necessary and suffi-
cient for Smt3p (yeast homologue of SUMO) activa-
tion in vitro [30]. The human homologue hUBA2 was 
shown to act in the same way[31]. Subsequently 
SUMO is transferred from UBA2 to the SUMO con-
jugating enzyme UBC9 [14, 32]. UBC9 recognizes the 
consensus sequence ΨKXE where Ψ is a large hy-
drophobic amino acid and K is the lysine for SUMO 
conjugation[33]. UBC9 is believed to be the only 
SUMO conjugating enzyme[32, 34] and SUMOylation 
of its binding partners is enhanced by interaction 
with p14ARF[35]. Finally, an isopropyl bond between 
the terminal glycine of SUMO and the ε-aminogroup 
of lysine of the target protein is formed by an E3 li-
gase. Several unrelated proteins have been attributed 
E3 SUMO ligase activity: nucleoporin protein 
RANBP2[36], TOPORS[37, 38], several PIAS pro-
teins[39-41], polycomb group protein Pc2[42], and 
RNF4[43]. Recently an anti-SUMO ubiquitin-protein 
isopeptide ligase (E3) has been described : mel-18 in-
teracts both with HSF2 and the SUMO E2 UBC9 and 
inhibits UBC9’s activity which decreases HSF2 SU-
MOylation[44]. 
Because of the many associated proteins, 
PML-NBs are involved in a wide variety of cellular 
processes such as DNA damage and repair[45, 46], 
apoptosis[47-49], senescence[50, 51], cell cycle[52], 
transcription[53], carcinogenesis[54] and virus infec-
tion[55, 56]. Despite the involvement in such vital 
processes, PML deficient mice are normal, fertile and 
do not have a higher occurrence of tumors [57]. Al-
though the actual function of the bodies still has to be 
determined, three non-mutually exclusive hypotheses 
about the function of PML-NBs have been proposed 
in literature. The first hypothesis gives PML-NBs a 
role as a nuclear depot thereby providing a mechanism 
for  regulating nucleoplasmic levels of proteins in 
which PML  bodies release proteins as they are 
needed[58]. Since nascent RNA has been found in the 
proximity of the PML-NBs[59]  and PML-NBs seem 
to associate in regions with high transcriptional activ-
ity[60, 61], the second hypothesis proposes that 
PML-NBs are associated with nuclear activity such as 
gene transcription and DNA replication [62]. Indeed, 
most well-described partners of PML-NBs such as 
p53, Daxx, Mdm2 and Sp100, all have transcription 
activation or repression activity [4, 49, 63-66]. Fur-
thermore, PML-NB structure is dependent on the in-
tegrity of the surrounding DNA. In fact, many factors 
which accumulate in PML-NBs are known histone 
methyltransferases, histone deacetylases or DNA 
methyltransferases, suggesting that PML-NBs may 
play an important role as epigenetic regulator of 
transcription and replication (for a review see [67] 
and references therein).  The third hypothesis is that 
PML-NBs provide a nuclear platform for 
post-translational modification (PTM) such as phos-
phorylation [68, 69], acetylation[70] and SUMOyla-
tion[71].   
These three hypotheses support the concept of 
dynamic interactions with PML and a high turnover 
of protein associates, instead of a static complex with 
a fixed number of partners. The involvement of 
PML-NBs in such a variety of processes has led to an 
enormous research interest in this enigmatic protein 
which has culminated in an overwhelming number of 
publications. In recent years, several techniques such 
as affinity capture, yeast two hybrid, co-localization 
and mass spectrometry have been employed to iden-
tify proteins of the PML complex which could lead to 
a better understanding of the PML-NB function. This 
reductionist approach has successfully identified 
several of the components of the PML-NBs but added 
more pieces to the puzzle instead of narrowing the 
spectrum of possible functions. Therefore an integra-
tive “Systems Biology” approach could be essential to 
grasp the true complexity of the PML-NBs and to al-
low us to generate hypotheses based upon the vast 
amount of information available in distributed 
sources.  
Not all PML partners described in literature are 
well represented in protein databases such as 
IntAct[72], Molecular Interactions Database 
(MINT)[73], BIOGRID[74], Human Protein Reference 
Database (HPRD)[75] and Nuclear Protein Database 
(NPD)[76]. This paper attempts to bridge the gap 
between (the lack of) database content and literature 
information. An integrated view of all the existing 
information is indispensable to gain true under-
standing of the functionality of large protein com-
plexes such as PML-NBs. 
We present a curated network model of 
PML-NBs based on information extracted from pro-
tein interaction databases (MINT, IntAct, BIOGRID, 
HPRD and NPD) and fragmented information ob-
tained through extensive literature search. For the 
compilation of the network we used the open source 
network analysis software Cytoscape. It features high 
flexibility and the possibility to analyze protein net-
works with various (downloadable) plug-in software 
extensions allowing us to analyze and interpret the 
collected PML network. Based on this model we offer 
a system-wide perspective on the pathways and pro-
teins that gather at the nuclear bodies. The network is Int. J. Biol. Sci. 2010, 6 
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publicly available (Proteomics division at 
http://www.ua.ac.be/ppse) to make it a central in-
formation resource for “PML-omics” researchers.   
Compiling a manually curated PML-NB 
network 
A manually curated PML-NB interaction net-
work was established in Cytoscape[77] by integration 
of PML interaction data retrieved from databases and 
literature (figure 2).   
First we assembled a primary PML-NB network 
established with data retrieved from protein data-
bases i.e. MINT[73], BIOGRID[74], HPRD[75], 
NPD[76] and IntAct[72]. Second, we expanded the 
primary network by adding PML-NB components 
which were exclusively found through extensive lit-
erature (only peer-reviewed journals) search. Finally, 
to create a biologically relevant network, interactions 
between PML-NB associated proteins were retrieved 
with the aid of Cytoscape import tools. Via the Uni-
ProtID we searched the    IntAct and cPATH database 
[78] to further complete the network. After importing 
all available data from these databases the informa-
tion was confirmed or completed by searching the 
BIOGRID, HPRD and MINT databases also using the 
UniProtID. Interactions found by cPATH and IntAct 
exploration which could not be verified in other da-
tabases were manually checked in literature. 
To compile the network, PML was the only pro-
tein used as PML-NB determinant. Often Sp100 or 
Daxx are used as PML-NB determinants but these 
proteins also dynamically move in and out of the 
PML-NBs[59]. This makes PML the only protein 
which always defines the PML-NBs.   
Interesting is the presence of a sub-network dis-
playing Alt-associated-PML nuclear bodies (APBs) 
(figure 2, boxed). These special PML bodies are only 
seen in a subset of interfase nuclei in telom-
erase-negative immortalized human cells. These cells 
maintain their telomeres by a mechanism known as 
alternative lengthening of telomeres (ALT). Thus far, 
APBs have not been observed in mortal cells or te-
lomerase positive immortal cells [79, 80]. In the APB, 
PML co-localizes with telomere binding proteins 
TRF1 and TRF2, Replication Protein A, RAD50, 
RAD51, RAD52, RAP1, Mre11, TIN2 and 
NBS1/p95[79, 81-84]. For RAD51 and RAD52 there is 
no evidence yet but all other components, including 
PML are required for APB formation [85]. The func-
tion of these bodies remains unclear. It is suggested 
that PML is required for the transcriptional activation 
of p53 in ALT cells and thus induces apoptosis via the 
p53 pathway[86]. 
After integrating the PML-NB components from 
database search and literature the network contains 
166 nodes (proteins) and 781 edges (interactions). To 
provide an overview of the characteristics of the 
PML-NB components and interactions which connect 
these we provide several edge and node attributes 
(Table 2). The criteria used to annotate these attrib-
utes are standardized and the order in which several 
sources are used is strictly maintained.   
Whereas in most publications only the most 
common PML-NB partners are mentioned, this is the 
first time PML-NB components are brought together 
in a comprehensive network. Depending on the re-
searcher’s interest, the network can be analyzed from 
different angles, eventually using additional tools 
such as cytoscape plugins.   
Analyzing the PML-NB interactome 
We analyzed the general properties of the 
PML-NB components using the attributes described 
above in table 2. The network contains 166 protein 
associates of PML of which 70 are described in litera-
ture but are not available in any of the standard pro-
tein interaction databases. 
The majority (57%) of the PML-NB proteins are 
nuclear, 33% of the PML-NB interactome shuttles ac-
tively between nucleus and cytoplasm, while 9% of 
the components are predominantly cytoplasmatic.   
To provide an overview of the processes in 
which PML-NBs are involved, we categorized the 
UniProt function keywords in groups and distributed 
the 166 PML-NB partners in these groups. It is possi-
ble that one protein simultaneously belongs to several 
groups. Figure 3 shows the functional distribution. 
The representation of proteins involved in transcrip-
tion regulation is remarkably high. As expected, most 
of these proteins appear t o  b e  n u c l e a r  o r  n u -
cleus/cytoplasm shuttles. Another interesting and 
well represented group involves proteins which are 
part of the virus host interaction. Proteins belonging 
to this group are mostly shuttles between cytoplasm 
and nucleus. These shuttles emphasize once more the 
role of PML-NBs in viral infection[93]. In addition, 
PML nuclear bodies have been implicated in proc-
esses as apoptosis and cell cycle it is not surprising 
that many of the protein partners are directly in-
volved in these processes. An interesting group is the 
one of the small protein conjugation, e.g. ubiquitin 
and SUMO, which is found under “PTM (small pro-
tein)” in the figure 3. Int. J. Biol. Sci. 2010, 6 
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Figure 2. A manually curated PML-NB network. The central node is the scaffold protein PML. PML-NB components are 
connected to PML. Black edges represent protein components found in any of the databases (MINT, BIOGRID, IntAct, NPD, 
HRPD), pink edges were exclusively found in literature. We also represent the interactions between PML-NB components 
which are depicted as blue edges. For each node we provided the canonical name. Boxed components are those exclusively 
found in ALT cells. 
 
 
 
Table 2. Overview of the different node and edge attributes in the PML-NB interaction network. In the ‘field’ column we 
present the attribute as it is assigned in the network. In the ‘description‘ column we provide a brief explanation of what is 
embodied by the attribute. Finally, in the ‘criteria’ column the different sources of information are mentioned. 
Field Description  Criteria  (in  order) 
Node Attributes 
ID  UniProtID [87]  Retrieved from UniProt 
Canonical Name  Common name  Most used in literature > First desig-
nation in UniProt 
Cellular Localization  Subcellular localization differentiates amongst the several organelles 
in the nucleus and cytoplasm. 
GO (cellular component ontology) > 
Locate [88] (marked with “*”) > Lit-
erature > predicted localization by 
Locate 
Simplified Cellular Localiza-
tion 
Only differentiates between nucleus, cytoplasm and shuttles between 
these two compartiments. 
‘nucleus’ (all nuclear organelles); ‘cy-
toplasm’ (all cytoplasmatic organelles) 
and ‘shuttle’ between cytoplasm and 
nucleus. 
Function  For this attribute we used the UniProt ontology as a simplified version 
of the GO terms to provide a comprehensible overview. To annotate 
the network with the complete GO annotations we refer to Cytoscape 
plugins such as BINGO[89]. 
UniProt Ontologies > Panther data-
base [90]  
Connection with disease  This field is filled in when mutations, knockout or other modifications 
of the protein resulting in disease. If a MIM number was available it is 
mentioned, otherwise there is reference to specific publications. This 
attribute is additional information and does not mean that the 
PML-NBs are explicitly involved in the disease process. 
UniProt (General Annotation) and 
literature 
Induction  Information from UniProt and literature about regulation by several 
(bio)chemical stimuli. 
UniProt (General Annotation) and 
literature 
SUMO Consensus  We manually searched if any PML-NB components contained a pre-
dicted negatively charged amino acid-dependent sumoylation motif 
(NDSM)[91] or phosphorylation-dependent sumoylation motif 
(PDSM)[92] and present these in this attribute. Proteins predicted by 
us are labeled as ‘IS Lab’. 
Literature 
SUMO Isoform  Here we provide an overview of the conjugated isoform described in 
literature. Proteins marked in this attribute with ‘pathway’ are en-
zymes or actors of the SUMO conjugation machinery. 
Literature 
Remarks  In the ‘Remarks’ attribute we provide potentially important details 
about the protein 
Literature and/or UniProt 
Edge Attributes 
Author(s)  Reference to the first author, year of publication and PubMedID.  PubMed 
Source  Indication of source where a certain interaction was found.  Literature and/or database (IntAct, 
HPRD, BIOGRID, MINT and NPD) 
search 
Methods  Gives an overview of the methods used to detect the interaction. As a 
designation for these methods we used the same evidence code as used 
on BIOGRID. 
Literature and/or database (IntAct, 
HPRD, BIOGRID, MINT and NPD) 
search 
Fluorescence Microscopy  Gives details about the conditions for co-localization studies e.g. en-
dogenous levels, overexpression data and or partial overlap (if men-
tioned in the publication) 
Literature 
Cell type  Cell type used for PML interaction studies.  Literature 
PML isoform  For PML interactions it is important to make reference of the PML 
isoform used if this data is available. 
Literature 
Remarks  In the ‘Remarks’ attribute we provide potentially important details 
interaction 
Literature 
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Figure 3. Functional distribution of the PML-NB components. For each functional category the number of nuclear, cyto-
plasmatic and shuttle proteins are plotted. The categories were based on the keywords in UniProt Ontologies. Several 
related categories were merged to facilitate interpretation, such as ‘intracellular signaling’ (merge of Notch signaling, Wnt 
signaling, signal transduction and intracellular signaling ontologies), ‘differentation and growth’ (merge of growth, differen-
tiation, muscle development, spermatogenesis and neurogenesis), ‘PTM (chemical)’ (acetylaction and phosphorylation), 
‘RNA processes’ (RNA splicing, catabolism and processing), nuclear structure (chromatin and centrosome) and miscella-
neous (lipid metabolism, oncogene and phagocytosis). 
 
The information embedded in the edges illus-
trates the diversity of techniques underlying the inte-
grated data that have been used to detect interactions 
with PML. Affinity capture, in vitro reconstitution of 
protein complexes and co-localization by im-
munofluorescence are the most commonly used 
methods to detect interactors of the PML-NBs. Fur-
ther research will demonstrate if components found 
with these methods interact binary with PML. Less 
frequently used are the two-hybrid methodology or 
biochemical assays, two techniques which do in fact 
prove binary interactions with PML.   
Of the total number of PML-NB components 
(166), 59% of the interactions were proven with only 
one technique. One must therefore keep in mind that 
false positives may be present in the network.   
Experiments were performed in diverse cell 
types which range from commonly used immortal 
lines such as HeLa, MCF-7 and HEK293 to primary 
cell cultures. Using several cell lines gives an overall 
idea of the composition of the PML-NB which is 
relevant for integration in systems biology and con-
tributes to the knowledge of PML–NB composition in 
different cell types. However, this generalization has 
to be treated with caution. The possibility exists that 
w e  a d o p t  c e r t a i n  p r o t e i n s  a s  p a r t  o f  t h e  c o m p l e x  
while this architecture is unique for a certain cell type 
(e.g. ALT cells). Equally important to create a uniform 
view of the PML protein complex is the necessity to 
clearly state –if possible- which isoform was used. 
Since PML has 6 different splice variants with differ-
ent kinetics [9], it is expected that these isoforms may 
(partially) bind other partner proteins. In only one 
third of the cases the PML isoform was clearly stated. 
Thus far the most used isoform is PMLIV. Therefore, 
to determine isoform-dependent differences in 
PML-NBs it is vital that researchers clearly state 
which PML variant is used in their experiments 
whenever possible. 
Apart from the direct interactions with PML, we 
imported the links between the several PML partners 
from the IntAct database to show distinct biological 
pathways that meet at the PML-NBs. Hence, next to 
the direct edges (166) with PML, these 166 partners 
are interconnected by 615 edges (figure 2).   
Upon analyses of the functions of the PML-NB 
components, a significant number of mostly nuclear 
proteins seems to be involved in ubiquitin-like modi-
fication processes such as SUMOylation and ubiquit-
ination (figure 3, PTM (small protein)). Due to the Int. J. Biol. Sci. 2010, 6 
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close relationship between PML SUMOylation and 
NB formation[10, 11, 94, 95] and because of PML-NBs 
may act as a platform for post-translational modifica-
tions; we explored the possibility if the PML-NBs 
could be SUMOylation hotspot in the nucleus. 
Are PML-NBs SUMOylation hotspots in the 
nucleus? 
PML-NBs are a hub for numerous proteins and 
are involved in a range of functions. Moreover, the 
complex is highly dynamic and proteins such as CBP 
and Sp100 show a dynamic exchange between nu-
clear bodies and nucleoplasm[96].   
We wondered if the dynamics of the complex 
would be related to SUMOylation of NB proteins. 
Thus, the PML-NBs would be a (de)SUMOylation 
platform where SUMO is coupled or detached 
to/from its target protein. Possible evidence con-
firming this hypothesis lies in the observation that a 
large number of confirmed SUMOylated proteins 
localizes at the NBs. In fact, apart from SUMO4, all 
SUMO isoforms are found in the PML-NBs. Further-
more, not only several SENPs were co-localized with 
PML but also activating enzyme UBA2[97], the only 
SUMO conjugating enzyme UBC9[98, 99] and several 
SUMO ligases such as RANBP2 and PIASy [100-103] 
(Figure 4). One of these, RANBP2, promotes PML 
SUMOylation [104]. In addition, another PML-NB 
component, HDAC7, has been described to exert 
“SUMO E3 ligase-like” activity and also enhances 
SUMO modification of PML [105]. In fact, the most 
interesting SUMO E3 ligase at the PML-NBs could be 
PML itself. Indeed, in yeast, the RING domain of 
PML is sufficient for PML auto-SUMOylation and 
SUMOylation of other proteins [106]. Moreover, in 
transfected mammalian cells, PML RING mutants 
show a dramatical decrease in PML 
auto-SUMOylation [107]. In vitro, when purified PML 
is incubated with HeLa lysate, UBC9 and SUMO1, 
this leads to auto-SUMOylation [98]. PML was al-
ready described to mediate SUMOylation for proteins 
such as YAP1 [108]. However, one must keep in mind 
that, although all these observations suggest a SUMO 
E3 ligase activity for PML, indirect effects (e.g. 
stimulation or increased expression of enzymes from 
the SUMOylation machinery) may also be involved 
and further research is required to define PML as a 
novel SUMO E3 ligase. 
Dynamics between SUMOylation and 
de-SUMOylation seems important for the architecture 
and function of the nuclear bodies. In fact, manipula-
tions of SENPs show distinct effects on PML-NBs. It 
has been shown that IL6 cytokine induces the 
upregulation of mRNA expression of SENP1. Aug-
mented SENP1 expression causes PML 
de-SUMOylation which abolishes the suppressor ac-
tivity of PML on STAT3 [109]. On the other hand, 
suppression of SENP1 increases the number of SU-
MOylated proteins and the size of the PML-NBs[110]. 
SENP2 co-localizes with PML-NBs and PML en-
hances its effects. SENP2 hydrolyses SUMO1 from 
PML in vitro and changes the cellular localization of 
PML protein partners such as CBP, Daxx and 
p53[111]. Further on, truncated SENP5 co-localizes in 
the PML-NBs instead of in the nucleolus and both 
truncated- and wild type-SENP5 show the ability to 
remove SUMO2 or SUMO3 from  PML  Lys160 or 
Lys490[26]. Finally, SENP6 suppression results in the 
accumulation of SUMO2/3-modified species in PML 
bodies [29] but SENP6 has not been co-localized with 
PML yet. These observations suggest that not only 
PML is influenced by the presence of SENPs but that 
they also  h ave an  effect on other PML-NB targeted 
proteins. 
All the necessary components to attach SUMO 
to a target are present at the PML-NBs but also the 
SENPs to remove SUMO again. This means that the 
complete cycle of SUMOylation and de-SUMOylation 
could take place at the PML-NBs (figure 4). In fact, 
PML contains a SUMO binding motif which forms a 
non-covalent interaction with SUMO attached to 
protein partners[107]. Possibly these proteins are re-
cruited to make a functional switch at the PML-NBs 
by detachment of SUMO.   
A large amount of PML partners have been de-
scribed in literature as SUMOylated (38%). However, 
this percentage may well be an underestimation be-
cause SUMOylation of many PML partners has not 
been investigated yet. Therefore, to have an idea 
about other possible SUMOylation targets in the 
network we searched for PML-NB proteins with an 
negatively  charged amino acid-dependent sumoyla-
tion motif  (NDSM) motif as predicted by Yang et 
al.[91]. In fact, more than 56% of the PML-NB com-
ponents contain an NDSM motif of which about half 
was already found to be SUMOylated in “wet lab” 
experiments.  
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Figure 4. Representation of the SUMOylation pathway in relation to the PML-NB. Indicated are the proteins which have 
been linked to PML (blue, linked with PML).  SUMO is synthesized as an immature protein which needs processing by 
SENPs. SENP1, SENP2 and SENP5 exert processing activity and have been linked to the PML-NBs implying that maturation 
may take place at the NBs. After maturation, the SUMO protein is activated by two E2 enzymes of which UBA2 was 
co-localized with the PML-NBs. Also the only conjugating UBC9 can be found in the PML-NBs and molecules which influence 
UBC9 such as p14ARF and MEL-18 have been targeted to the PML-NBs. For final conjugation of SUMO to a target protein, 
an E3 ligase is needed and apart from PML which potentially contains E3 activity itself, four other ligases (TOPORS, RNF4, 
RANBP2, PIASy) have been targeted to the NBs. We propose that the target protein, the E3 ligase and UBC9-SUMO meet 
at the nuclear bodies for the completion of the SUMO pathway. Finally, SUMOylation can be reversed by SENPs. Only 
de-conjugation SENP3 and SENP7 have not been linked to the PML-NBs thus far.  
 
In-house prediction of SUMOylation targets 
Complementary to existing knowledge of SU-
MOylation sites, we employed an in-house developed 
machine learning approach to predict genome-wide 
SUMOylation sites.   
We used the method based on Conditional 
Random Fields that previously proved successfully to 
predict kinase specific phosphorylation sites[112]. A 9 
residue sequence window surrounding the annotated 
SUMOylation sites from UniProt was used to train a 
Conditional Random Field-based model as described 
in Dang et al. (2008)[112], with a feature function 
template optimized with a Genetic Algorithm as de-
scribed in Dang et al. (2009) (in publication).    Known 
SUMOylation sites were extracted from UniProt 
(downloaded august 18, 2009) based on the sequence 
feature "CROSSLINK" and a feature description con-
taining the string "SUMO". Feature annotations con-
taining the "probable" or "by similarity" qualifiers 
were removed. This data was used as training and 
test data. 
The performance of the training step was as-
sessed by k-fold (k=4) cross validations. In four fold 
cross validation, the protein set is partitioned into 
four subsets, of these subsets a single subset is re-
tained as validation data for testing the model. The 
remaining three subsets are used as training data. 
This process is repeated four times with each of the 
four subsets used exactly once as the test set. 
The resulting Receiver Operator (ROC) curve is 
shown in figure 5a. Its excellent performance is Int. J. Biol. Sci. 2010, 6 
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demonstrated by an Area Under the Curve (AUC) 
value of 0,91. Also in figure 5 is a Venn-diagram of 
the overlap of what is described in literature and 
what is predicted. In general there is a large overlap 
between our screening method and the search for 
NDSM motifs[91]. We determine fewer proteins as 
SUMOylation target compared to the NDSM paper, 
which is determined by the stringency of our thresh-
old. We chose to include only few insecurities and 
high confidence in our predictions. Figure 5b demon-
strates that the overlap between literature and our 
approach and the overlap between the NDSM predic-
tions and literature is equal, even though Yang et al. 
found more unconfirmed targets. Interestingly, there 
appears to be a portion of targets which were not 
predicted by our method or the method of Yang et al., 
suggesting that there are other motifs and surround-
ing amino acids which characterize a SUMOylation 
target. 
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Figure 5. A. Receiver Operator Curve (ROC) of our in-house prediction algorithm with Area Under the Curve (AUC) 
value of 0,91. B. Overlap between literature, our predictions and the predictions performed by Yang et al.. Due to the 
different approach there are some unique prediction data for both our prediction method and the predictions performed by 
Yang et al.. C. Predicted percentages by our in-house algorithm (FPR =1%). Genome-wide we predict about one fourth of 
the proteins to be SUMOylated. Membrane and extracellular proteins are less likely to be SUMOylation targets then cy-
toplasmatic or nuclear proteins. Within the PML-NBs we see a clear enrichment of SUMOylatable proteins. 
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To asses a potential enrichment of SUMOylated 
proteins at the PML-NBs, percentages of predicted 
SUMOylated proteins were compared between the 
full human proteome and the PML-NB. 
To accomplish this, the trained model was used 
to predict potential SUMOylation sites in the full 
human proteome (using the UniProt sequences), with 
a predefined maximum allowed false positive rate 
(FPR) of 1% as described in Dang et al.[112]. Figure 5c 
gives an overview of the predicted percentages of 
SUMOylatable proteins in several cellular compart-
ments. Genome wide about 24% of the protein se-
quences contained at least one predicted potential 
SUMOylation site.  Within proteins annotated with 
the GO Cellular component terms "cytoplasm" and 
"nucleus", respectively 26% and 33% were predicted 
to contain one or more SUMOylation sites. Within the 
assembled PML network, 48% contained 1 or more 
predicted SUMOylation motifs, demonstrating a clear 
overrepresentation of SUMOylation motifs in the 
PML network that cannot solely be attributed to its 
nuclear localization. 
Since our predictor is trained with all possible 
known SUMOylation sites, its predictions are not fo-
cussing on one particular motif (such as the NDSM 
motif) but on all possible motifs. Together with the 
excellent performance demonstrated by the ROC 
curve and the stringent thresholds applied, we be-
lieve that this is the most reliable approach to be able 
to draw conclusions from the intracellular distribu-
tion of predicted SUMOylation sites. The observed 
discrepancies between our predictor and the NDSM 
results may, besides algorithmic performance differ-
ences, also reflect the diversity of the training se-
quences and the stringency of the performed predic-
tion. 
Conclusion 
Dynamic complexes such as the PML-NBs re-
quire high-throughput methods as well as specialized 
reductionist approaches for characterization and 
identification of all the participating components. As 
much, the PML community should be cautious for 
scattered data making it difficult to maintain a gen-
eral overview. We believe that our PML network 
helps in giving a comprehensive insight in the vast 
amount of PML data that has been generated.   
Creating this overview focused the attention on 
a role of the PML-NBs in SUMOylation. The presence 
of the enzymes for both SUMOylation and 
de-SUMOylation suggests that both the attachment 
and detachment of SUMO can take place at the 
PML-NBs. In fact, the properties of the PML protein 
such as the RING domain and coiled coil motif are 
ideal to recruit unmodified proteins which are targets 
for SUMOylation. Amongst others, PML itself may 
act as an E3 SUMO ligase. In addition, PML contains 
a SUMO binding motif that can bind SUMOylated 
proteins which might be in turn de-SUMOylated. 
To estimate if there was an enrichment of possi-
bly SUMOylated proteins at the PML-NBs, inde-
pendent of cellular localization, we used an in-house 
prediction method for a genome wide screen for 
SUMOylatable proteins. We show that 24% of the 
p r o t e i n s  g e n o m e  w i d e  i s  predicted to be SUMOy-
lated. Although in the nucleus this number rises 
slightly to 33% we found that 48% of the PML-NB 
components contain one or more possible SUMOyla-
tion sites. This suggests that the PML-NBs are en-
riched sites for SUMOylated proteins. 
Taken together the presence of 
(de)-SUMOylation enzymes combined with an en-
r i c h m e n t  i n  S U M O y l a t a b l e  p r o t e i n s  s u g g e s t s  t h a t  
PML-NBs are a hotspot for nuclear SUMOylation 
where protein targets meet the components of the 
(de)-SUMOylation pathway. 
The dynamic regulation of key point proteins at 
the PML-NBs supports this hypothesis since the 
regulatory function of SUMOylation on PML-NB re-
lated processes such as  transcription [14, 113, 114], 
cell cycle[115], apoptosis[116], senescence[117] and 
viral infection [118-120] is slowly uncovered. As an 
example we present in table 3 the influence of SU-
MOylation on PML-NB related transcription factors.   
Further, this hypothesis could be the glue be-
tween the three previously formulated hypotheses 
about PML-NB function.  Since SUMOylation is of-
ten related to a functional switch, it is not unthinkable 
that by SUMOylation certain protein factors are re-
tained in the nucleus until they are needed and are 
released by de-SUMOylation or vice versa. This SU-
MOylation dependent switching could meticulously 
regulate specific nuclear processes such as transcrip-
tion and DNA related processes. In fact, our func-
tional analysis reveals a very high number of tran-
scription factors confirming the close relationship 
between PML-NBs and the modulation of transcrip-
tion, possibly in a SUMO-dependent manner. Simi-
larly, several protein partners are involved in DNA 
replication, damage sensing and repair which indi-
cate a role in DNA related processes including epi-
genetic regulation [67]. 
The PML-NBs can thus be seen as a nuclear re-
lay station where protein fractions involved in a vari-
ety of nuclear processes make a SUMOylation regu-
lated functional switch. In addition, it is important to Int. J. Biol. Sci. 2010, 6 
 
http://www.biolsci.org 
62
state that SUMOylation itself is regulated. Increas-
ingly, the crosstalk between SUMOylation and other 
PTMs such as acteylation and phosphorylation (e.g. 
via the PDSM SUMOylation motif [92]) is uncovered 
[121, 122]. Since at the PML-NBs also kinases, acetyl-
transferases and methyltransferases gather, it is likely 
that we are just exploring the borders of the regula-
tory complexity within this protein complex. 
 
Table 3. Effect of SUMOylation on transcription factors present in the PML-NBs. Several transcription factors have a 
predicted PDSM motif but have not been shown to be SUMOylated (ARI3A, Ataxin7, FLASH, HDAC2, HHEX, HIRA, LBP1, 
mTOR, MZF, NCOR1, NR4A1, PAR4, PAX5, SIRT1, SKI, SP140, THAP1 and ZNF24). About the remainder of the tran-
scription factors associated with PML-NBs there is no available data regarding SUMOylation. 
UniProtID Name  Motif  Residue  Effect of SUMOylation  Positieve/negative 
Effect (+/-) 
P27540  ARNT  NDSM  K245  SUMOylation affects the ability of ARNT to interact with cooperative 
molecules such as PML[123] 
- 
Q9BYV9  BACH2  NDSM     SUMOylation is an important regulatory system for the mobility of the 
nuclear domains formed by Bach2[124] 
+ 
Q92793  CBP  NDSM     SUMO modification negatively modulates the transcriptional activity 
of CREB-binding protein[125] 
- 
P01100  C-FOS  NDSM   K299, K257 SUMOylation down-regulates c-Fos/c-Jun AP-1 dimer activity [126]  - 
P05412 C-JUN  NDSM    K257,  K 
229 
SUMOylation down-regulates c-Fos/c-Jun AP-1 dimer activity [126]  - 
P10242  C-MYB  N/PDSM K499, K523 SUMO1-ylation regulates the transactivation function of c-Myb[127]  - 
Q9UER7  Daxx     K630, K631 Role of Daxx SUMOylation unknown[125, 128]   
Q15910  EZH2  NDSM    Modulation of polycomb repressive complex 2[129]   
P23769  GATA2  NDSM    Negative regulation of transcriptional activity[130]  - 
Q13547  HDAC1  NDSM   K444, K476 SUMOylation reduces HDAC1-mediated transcriptional 
repression[131] 
- 
Q86Z02  HIPK1  NDSM    SUMOylation induces a cytoplasmic translocation leading to 
ASK1-JNK activation[132] 
+ 
Q9H2X6  HIPK2  NDSM  K25  SUMOylation inhibits HIPK2-induced JNK activation and 
p53-independent antiproliferative function[133] 
- 
Q03933  HSF2  NDSM   K82  SUMOylation of HSF2 results in conversion to the active DNA binding 
form[134] 
+ 
Q9UJU2  LEF1       SUMOylation induces potent repression of LEF1 activity[135]  - 
Q99607  MEF/ELF4     K657  SUMOylation down-regulates ELF4 activity[136]  - 
Q15596 NCOA2 
(human, 
GRIP1 mouse 
NDSM K239, 
K731, K788 
SUMOylation of GRIP1 (mouse equivalent of NCOA2) enhances 
binding to the androgen receptor[137] 
+ 
Q9Y618 NCOR2  N/PDSM    unknown   
O95644  NFAT  NDSM  K684, K897 SUMOylation of K684 is required for NFAT1 transcriptional activity, 
SUMOylation of K897 is only required for nuclear anchorage[138] 
+ 
O00482  NR5A2  NDSM   K173,K289  SUMOylation is associated with transcription repression[139]  - 
Q8N726  p14ARF     N/A  Not SUMOylated. Promotes SUMOylation by enhancing UBC9[35]  + 
P04637  p53     K386  SUMOylation induces premature senescence and stress response[116]  + 
Q9H3D4  p63     K637  SUMOylation has a negative effect on p63 driven transcription[140]  - 
O15350  p73     K627  SUMO1-ylation of p73 is involved its proteasome-dependent degrada-
tion, subnuclear localization and modulation of interactions with other 
SUMO1 substrates[116] 
- 
Q8N2W9  PIASy  NDSM  K35  SUMO1-ylation of PIASy is necessary for PIASy-dependent activation 
of Tcf-4[41] 
+ 
Q05516 PLZF  NDSM  K242, 
K387, K396 
SUMOylation enhances the transcriptional repression activity, corre-
lating with a loss of PLZF-mediated growth suppression[141] 
+ 
P29590 PML  NDSM    K65,  K160, 
K490 
 
SUMOylation is important for nuclear localization of PML and nuclear 
body formation[4] 
 
+ 
P06400  pRB  NDSM    SUMOylation induces premature senescence and stress response[142]  + 
P14373  RFP/TRIM27       SUMOylation strengthens the transcriptional repressive activity of 
RFP[143] 
 
+ 
P78317  RNF4     N/A  SUMOylation of RNF4 not shown, RNF4 is a SUMO-dependent Ubiq-
uitin ligase for poly-SUMOylated proteins[12] 
 
Q01826  SATB1  NDSM  K744  SUMOylation enhances caspase cleavage of SATB1[144]  - 
Q96ST3  SIN3A  NDSM     SUMOylation regulates tumorsupression of SIN3a[38]   
Q6PEW1  SIZN      SUMOylation mediates localization in PML-NBs[145]   
P84022  SMAD3       SUMOylation affects the DNA-binding activity of Smad3 and induces 
nuclear export[146] 
- 
P08047  SP1  NDSM  K16  SUMOylation inhibits cleavage of Sp1 N-terminal negative regulatory 
domain and inhibits Sp1-dependent transcription[147] 
- 
P11831  SRF  NDSM  K147  Activated SRF is suppressed by its SUMOylation[148]  - Int. J. Biol. Sci. 2010, 6 
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Q15022 SUZ12  NDSM  K72,  K73, 
K75 
SUMOylation modulates PRC2 repressive activity[129]  +/- 
Q9NQB0  TCF4  NDSM  K297  SUMOylation is involved in beta-catenin-dependent and 
Tcf-4-mediated gene expression in the Wnt signaling pathway[41] 
+ 
O15164 TIF1/TRIM24  NDSM    K690,  K708  unknown   
Q92993  TIP60  NDSM  K430, K451 SUMOylation of TIP60 augments its acetyltransferase activity in vitro 
and in vivo[149] 
+ 
P13056  TR2  NDSM    SUMOylated TR2 recruits corepressor RIP140 to act as a repressor for 
its target Oct4[150] 
- 
O95551 TTRAP        Unknown   
Q9UBW7  ZNF198     K963  SUMOylation of ZNF198 is important for PML body formation[151]  + 
Q9Y4E5  ZNF451  NDSM    ZNF451 exerts its effects via SUMOylation and trafficking of tran-
scription regulators between promyelocytic leukemia bodies and nu-
cleoplasm[152] 
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